ATTAIN-1 and ATTAIN-2: The Trials Behind the Foundayo Approval
Two 72-week randomized, double-blind, placebo-controlled trials supported the first approval of an oral small-molecule GLP-1 for obesity. Here is what they measured, what they found, and what they did not test.
Findings
- Approval was supported by the phase 3 ATTAIN program: two global, randomized, double-blind, placebo-controlled trials evaluating efficacy and safety over 72 weeks.
- ATTAIN-1 enrolled 3,127 adults with obesity or overweight.
- The highest dose produced an average of 12.4% weight loss in clinical trials.
- Gastrointestinal adverse events predominated, and discontinuations were higher with orforglipron than with placebo in both trials. Deaths were largely adjudicated as unrelated to treatment.
Program at a glance
Why a nonpeptide matters
Semaglutide is a peptide. Peptides are fragile in the gut, which is why oral semaglutide requires an absorption enhancer and a strict dosing routine around food and water. Orforglipron is a small molecule — a nonpeptide GLP-1 receptor agonist — and does not carry that constraint. It is a once-daily oral agent that can be taken at any time of day without food or water restrictions.
That is a formulation and adherence claim rather than a potency claim, and the two should not be conflated. The trials tested whether the drug works. The dosing flexibility is a property of the molecule, not a trial result.
The efficacy figure, in context
The number in circulation is an average of 12.4% weight loss at the highest dose. Three things are worth holding alongside it:
- It is a dose-specific figure. Lower doses produced smaller reductions. A patient who does not tolerate titration to the top dose should not expect the headline number.
- It is an average. Individual response in GLP-1 trials varies widely around the mean in both directions.
- It is not a head-to-head result. Neither ATTAIN trial was designed as a comparison against injectable tirzepatide or semaglutide. Cross-trial comparisons between separately designed studies with different populations are not evidence of superiority or inferiority.
Placing 12.4% next to a figure from a SURMOUNT or STEP trial and drawing a conclusion is the most common analytical error in consumer GLP-1 coverage. Different enrollment criteria, different baseline characteristics, different endpoints. Only a randomized head-to-head trial answers that question, and one has not been run here.
The safety picture
Gastrointestinal adverse events predominated, which is the expected profile for this drug class. Discontinuations were higher with orforglipron than with placebo in both trials — a figure that deserves more attention than it usually receives, because tolerability is what determines whether a patient ever reaches the dose that produces the headline result.
Deaths in the program were largely adjudicated as unrelated to treatment.
The approved labelling carries a boxed warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma. The drug should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Commonly reported adverse effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair loss.
- How orforglipron performs against injectable tirzepatide or semaglutide in a randomized head-to-head design.
- Durability of weight reduction beyond the 72-week trial window.
- Weight regain trajectory after discontinuation.
- Real-world adherence, which the boxed dosing-flexibility advantage is intended to improve but which no trial has yet measured outside a study setting.
- Long-term thyroid C-cell tumor incidence — the subject of an FDA-required postmarketing registry study running for at least 15 years.
What comes next in the program
The obesity indication is not the end of the development path. Eli Lilly has stated it plans to submit an additional application to the FDA for orforglipron as a treatment for type 2 diabetes, based on findings from the phase 3 ACHIEVE program, which evaluates the once-daily oral agent for glycemic control and cardiometabolic outcomes in adults with type 2 diabetes. The molecule is also being studied for obstructive sleep apnea and hypertension in adults with obesity, and a separate program is recruiting in participants with obesity or overweight and osteoarthritis of the knee.
Each additional indication is a separate evidentiary question. Approval for obesity says nothing about whether the drug will be approved for any of them.
Primary sources & citations
- US Food and Drug Administration press announcement on approval of Foundayo (orforglipron), April 1, 2026.
- Pharmacy Times, coverage of the orforglipron approval and the ATTAIN-1 and ATTAIN-2 trial results.
- HCPLive, Diabetes Dialogue coverage of the orforglipron approval and phase 3 ATTAIN program design, April 1, 2026.
- AJMC, reporting on the Foundayo boxed warning and reported adverse effects.
- MedCentral, reporting on the ACHIEVE phase 3 program and planned type 2 diabetes application.
- ClinicalTrials.gov records for orforglipron (LY3502970) study programs.
Editorial note
Looking for a provider rather than a citation?
This site does not review or rank telehealth providers inside its research articles, and carries no provider links in article text. Our provider comparison grid, including how each one is monetized, lives on the homepage.
Open the provider grid